|
A Circulating Biomarker for use in Monitoring Metastatic Breast Cancer
|
2R44CA210817-02
|
$1,101,350
|
|
SERRERO, GINETTE
|
A AND G PHARMACEUTICAL, INC.
|
|
Innovation Corp Program and Commercialization Planning for Endoscopic Flexible Pancreatic Tumor Ablation System with Reduced Force Effector and Specialized Ablation Zone
|
3R43CA225169-01S1
|
$49,999
|
|
SNOOK, KEVIN
|
ACTUATED MEDICAL, INC.
|
|
Fluorescent Nanodiamonds for Multiplexed Imaging and Diagnostics
|
1R43CA232901-01
|
$291,083
|
|
SHENDEROVA, OLGA
|
ADAMAS NANOTECHNOLOGIES, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation
|
1R43CA232977-01
|
$298,444
|
|
MARLEAU, ANNETTE
|
AETHLON MEDICAL, INC.
|
|
Training African Pathologists in Cancer Diagnosis
|
1R13CA232439-01
|
$38,120
|
|
WILSON, MICHAEL
|
AFRICAN STRATEGIES /ADVANCING PATHOLOGY
|
|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-04
|
$701,778
|
$56,142
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Integrative Molecular Epidemiology Workshop
|
2R25CA174664-06
|
$258,400
|
|
SELLERS, THOMAS
|
AMERICAN ASSOCIATION FOR CANCER RESEARCH
|
|
Therapeutic peptide for hepatocellular carcinoma
|
1R43CA232947-01
|
$299,983
|
|
PANDEY, NIRANJAN
|
ASCLEPIX THERAPEUTICS, LLC
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
P53-dependent immunogenic DCs in the tumor microenvironment
|
1R50CA232983-01
|
$203,853
|
|
SHARMA, MADHAV
|
AUGUSTA UNIVERSITY
|
|
DT-EGF Toxic Fusion Protein for the Treatment of Bladder Cancer
|
1R44CA232963-01
|
$299,937
|
|
GLODE, MIKE
|
AURORA ONCOLOGY, INC.
|
|
Rapid Non-Viral Platform for Generation of Genetically Modified T Cells for Therapy
|
1R44CA233143-01
|
$218,588
|
|
LAMPI HERMANSON, DAVID
|
B-MOGEN BIOTECHNOLOGIES, INC.
|
|
Minority PDX Development and Trial Center: Baylor College of Medicine and MD Anderson Cancer Center Collaboration on Mechanistic Studies to Dissect and Combat Health Disparities in Cancer
|
1U54CA233223-01
|
$6,353,982
|
|
MITSIADES, NICHOLAS
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
|
1U01DE028233-01
|
$536,395
|
|
SIKORA, ANDREW
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer Genetics Professional Education in a Global Community of Practice
|
2R25CA171998-06
|
$280,269
|
|
BLAZER, KATHLEEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Yes 2 Success
|
1R25CA233431-01
|
$485,999
|
|
KITTLES, RICK
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Role of Vitamin B5 and Coenzyme A Metabolism in PI3K Driven Tumorigenesis
|
4R00CA194314-03
|
$249,000
|
|
DIBBLE, CHRISTIAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Tissue-specific genetic interactions in cancer
|
1R01CA232372-01
|
$505,643
|
|
HAIGIS, KEVIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Parallel and high throughput isolation of cancer cell derived extracellular vesicles
|
1R43CA232848-01
|
$239,138
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
|
1R44CA224848-01A1
|
$348,768
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Cancer Imaging and Therapy Analysis Platform (CITAP)
|
2R44CA213601-02
|
$817,362
|
|
GARGESHA, MADHUSUDHANA
|
BIOINVISION, INC.
|
|
Biomedical Engineering Society Annual Meeting
|
1R13EB026960-01
|
$5,000
|
|
SETTON, LORI
|
BIOMEDICAL ENGINEERING SOCIETY
|
|
Detection of Methylation and Translocation Events by Novel Genomic Technologies
|
3R43CA214386-01S1
|
$50,000
|
|
PEYTAVI, REGIS
|
BLUENOVO BIOSYSTEMS, INC.
|
|
Development of a novel Antibody Drug Conjugate for the treatment of pancreaticcancer
|
1F30CA220843-01A1
|
$49,524
|
|
GROMISCH, CHRISTOPHER
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Determining the roles of the Hippo pathway kinases LATS1 and LATS2 in mammary gland homeostasis and disease
|
1F31CA232683-01
|
$44,524
|
|
KERN, JOSEPH
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
|
1U2CCA233238-01
|
$6,692,860
|
|
SPIRA, AVRUM
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
The novel PRMT5-substrate adaptor interface provides a therapeutic target in MTAP null tumors
|
1F32CA232543-01
|
$58,654
|
|
MULVANEY, KATHLEEN
|
BROAD INSTITUTE, INC.
|
|
Supine Breast MRI Standardization for Breast Cancer Locator
|
1R44CA232862-01
|
$221,343
|
|
KRISHNASWAMY, VENKATARAMANAN
|
CAIRNSURGICAL, INC.
|
|
CapioCyte circulating tumor cell assay as a biomarker for cancer immunotherapy response
|
1R43CA232924-01
|
$209,801
|
|
MILLER, STEVEN
|
CAPIO BIOSCIENCES, INC.
|
|
Develop a rapid, efficient and low cost extracellular vesicles isolation method toward non-invasive non-small cell lung cancer molecular analysis
|
1R43CA228847-01A1
|
$300,000
|
|
HE, HONGZHANG
|
CAPTIS DIAGNOSTICS
|
|
Transient anti-BCMA CAR T-cells for Treatment of Multiple Myeloma
|
1R43CA221432-01A1
|
$299,042
|
|
STEWART, CHARLES
|
CARTESIAN THERAPEUTICS, INC.
|
|
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
|
1F31CA221383-01A1
|
$42,074
|
|
BRAMAN, NATHANIEL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Novel Molecular Biomarkers and Therapeutics for Colorectal Cancer
|
1R50CA211119-01A1
|
$154,101
|
|
FINK, STEPHEN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center (Case CCC) Cancer Health Disparities SPORE Planning Grant
|
1P20CA233216-01
|
$1,062,400
|
|
LI, LI
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Targeting pancreatic cancers metabolic addiction to HuR
|
1R37CA227865-01A1
|
$401,484
|
|
WINTER, JORDAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Clinical Translation of a Caveolae Targeting Antibody for Enhancing Cancer Drug Delivery
|
1R41CA228841-01A1
|
$300,001
|
|
YANG, CHUN
|
CAVATAR, LLC
|
|
Advancing Analysis and Interpretation ofAdverse Events and PROs in Cancer Clinical Trials
|
1U01CA232859-01
|
$732,973
|
|
ROGATKO, ANDRE
|
CEDARS-SINAI MEDICAL CENTER
|
|
Specificity and safety of a targeted therapy against triple negative breast cancer
|
1R43CA224750-01A1
|
$300,000
|
|
IVANOVSKA, IRENA
|
CELDARA MEDICAL, LLC
|
|
Chemically produced neural progenitors loaded with ferumoxide-protamine sulfate complex for visualization of gliomas
|
1R43CA228726-01A1
|
$300,000
|
|
ALEXANIAN, ARSHAK
|
CELL REPROGRAMMING AND THERAPEUTICS, LLC
|
|
Air Pollution and HealthGeoHealth Hub Research and Capacity Building
|
5U01TW010097-04
|
$224,969
|
|
PRABHAKARAN, DORAIRAJ
|
CENTRE FOR CHRONIC DISEASE CONTROL
|
|
Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers
|
1U54CA232568-01
|
$12,197,183
|
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Center for pediatric tumor cell atlas
|
1U2CCA233285-01
|
$2,560,774
|
|
TAN, KAI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cassette exons in neoplastic pro-B-cells: implications for immunotherapy
|
1U01CA232563-01
|
$2,931,750
|
|
THOMAS-TIKHONENKO, ANDREI
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Enhancing cell therapy for brain tumors
|
1U01CA239258-01
|
$674,256
|
|
BOLLARD, CATHERINE
|
CHILDREN'S RESEARCH INSTITUTE
|
|
Highly Sensitive Chimerism Testing to Detect Early Leukemia Relapse Post-Allo-Transplantation
|
1R41CA232805-01
|
$173,566
|
|
KANAAN, SAMI
|
CHIMEROCYTE, INC.
|
|
Exploiting signals of cell-free DNA degradation for clinical research and cancer diagnostics
|
1R43CA232935-01
|
$298,559
|
|
HARKINS, KELLY
|
CLARET BIOSCIENCE, LLC
|
|
Pre-IND development of CBT-15 monoclonal antibody therapy against renal cell cancer
|
1R44CA228895-01A1
|
$298,835
|
|
SUREBAN, SRIPATHI
|
COARE HOLDINGS, INC.
|
Total relevant funding to Penis for this search: $651,482
|